Q3 2025 Arvinas Inc Earnings Call Transcript

Nov 5, 2025 / 01:00 PM GMT

Release Date Price: $9.57 (+0.31%)

Transcript 10-Q8-K

Key Points

Positve

Arvinas Inc (ARVN) has made significant progress in its clinical development programs, with multiple readouts from early-stage clinical programs and promising preclinical data.
The company has a strong track record of translating preclinical results into clinical successes, with a versatile platform that shows promise across various therapeutic areas.
Arvinas Inc (ARVN) has financial and strategic flexibility, with cash on hand projected to last into the second half of 2028.
The collaboration with Pfizer for the commercialization of Vettde is progressing, with a new drug application under review by the FDA and a potential partner being sought.
The company is actively pursuing innovative therapies in oncology and neurology, with a deep pipeline of clinical candidates and ongoing trials in areas of high unmet need.

Negative

Revenue for the third quarter of 2025 decreased significantly compared to the same period in 2024, primarily due to the expiration of a previous license agreement with Novartis.
General and administrative expenses have decreased, but this was largely due to the termination of a lease and reductions in personnel and infrastructure costs, indicating potential downsizing.
Research and development expenses have decreased, which could suggest a reduction in the scale or scope of ongoing projects.
The company has not yet achieved the predicted efficacious exposure level in its phase 1 monotherapy trial for ARV 393, indicating potential challenges in reaching desired clinical outcomes.
There is uncertainty regarding the timing and success of future clinical trials, with some programs still in early stages and dependent on forthcoming data to guide further development.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

ARVN.OQ - Arvinas Inc
Q3 2025 Arvinas Inc Earnings Call
Nov 05, 2025 / 01:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Thank you for standing by and welcome to our Venus

3rd quarter, 2025 earnings call. I'd like to remind everyone that this call is

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.